Please assess the completion status of the following clinical trial:

Trial Title: Multi-center Study to Transplant Hepatitis-C Infected Kidneys

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Recipient Inclusion Criteria:~* Estimated glomerular filtration rate(eGFR) \< 15 ml/min/1.73 m2~* Listed for an isolated kidney transplantation~* Able to understand and adhere to the study visit schedule and all other protocol requirements, and must voluntarily sign and date an informed consent~* No available medically acceptable, compatible living kidney donor~* Subject must agree to use an effective method of birth control per protocol specifications~Recipient Exclusion Criteria:~* History of severe, life-threatening or other significant sensitivity to immunosuppressants utilized in kidney transplant~* Female who is pregnant, breastfeeding, or is planning to become pregnant during the course of the study~* History of HIV~* HCV RNA positive~* HBV surface Ag-positive or detectable HBV DNA~* Primary focal segmental glomerulosclerosis (FSGS) or disease process with increased risk of causing early graft failure as assessed by the transplant nephrologist and/or investigator team~* Presence of clinically significant liver disease~* Transplant candidate requiring antibody desensitization protocol for transplantation~* Most recent calculated panel reactive antibody (cPRA) \>80%.~* Prior recipient of a non-renal solid organ transplant~Donor Organ Inclusion Criteria~* Deceased donor organ with kidney donor profile index (KDPI) ≤0.85~* HCV RNA-positive~Donor Organ Exclusion Criteria~* Known prior HCV treatment with direct acting antiviral medication~* HIV RNA-positive~* HBV Surface antigen-positive or HBV DNA-positive

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment with glecaprevir/pibrentasvir Fixed Dose Combination (Type: EXPERIMENTAL): 8 weeks of HCV treatment with combination tablet of glecaprevir and pibrentasvir

Based on this trial design, predict the completion outcome and termination type (if applicable).